Monday, January 21, 2013

ASH 2012: Dr. John Byrd Part 3 Accrual Issues in Clinical Trials, Transplant, CAR-T, the Rare Relapses, and Biological Combination

We are still in Ireland having an amazing time so I will be brief in posting the third of a four part ASH 2012 interview with Dr. Byrd.

In this segment we are  getting into some of the gritty details of treatment with ibrutinib. For the cognoscenti, this may add to your knowledge base. For those new to the ibrutinib story, I suggest you review my early ASH 2012 interviews with Dr. Pagel and the first two parts to this interview in my earlier posts.

To my non-CLL friends, I guarantee that soon I will share some amazing craic, photos, and video from Ireland. but right now, I am just having way too good a time to devote much attention to the internet.


Labels: , , , , , , , , ,

2 Comments:

Blogger Janet said...

Exciting Times

January 21, 2013 at 5:20 PM  
Anonymous Anonymous said...

I wondered if anyone has had any inflammatory process in the abdominal area while taking Ibrutinib?
I have had ascites on the liver and also ascites in the pelvic area. I am awaiting pathology reports after having specimens taken yesterday from nodules that are in my abdomen. I also had ovarian cancer 6yrs ago. I am hoping that it is all caused by inflammation from the Ibrutibib?

January 22, 2013 at 12:48 PM  

Post a Comment

Subscribe to Post Comments [Atom]

<< Home